Gauci L
Int J Cancer Suppl. 1987;1:21-30. doi: 10.1002/ijc.2910390706.
This is a review of the data on the safety and tolerance of interferon alfa-2a in the treatment of cancer patients and is particularly aimed at patient care. Since 1981, interferon alfa-2a prepared from human sources has been administered to over 2500 cancer patients and 2500 patients with viral diseases. Adverse effects have been invariably produced following parenteral injections of greater than 3 X 10(6) IU. These were mainly flu-like symptoms (greater than 90%), fatigue (90%), gastrointestinal (85%), central nervous system (65%) and musculoskeletal (60%) disorders. Laboratory abnormalities, though common (greater than 75%) were rarely dose limiting. Their severity can be reduced by using dose schedules which promote tachyphylaxis, co-medication with paracetamol and evening administration. Fatigue is best controlled by careful dose attenuation and occasional therapy rest periods. At dosages of 3 X 10(6)-18 X 10(6) IU/injection, interferon alfa-2a therapy can be safely managed on an out-patient basis, requiring minimal or no hospitalization. The frequency and low titre of antibody development to interferon alfa-2a indicates that it is a weak antigen and is suitable for long-term therapeutic application.
这是一篇关于干扰素α-2a治疗癌症患者安全性和耐受性的数据综述，尤其针对患者护理。自1981年以来，从人源制备的干扰素α-2a已用于2500多名癌症患者和2500名病毒疾病患者。肠胃外注射超过3×10⁶国际单位后总会产生不良反应。这些主要是类流感症状（超过90%）、疲劳（90%）、胃肠道症状（85%）、中枢神经系统症状（65%）和肌肉骨骼症状（60%）。实验室异常虽然常见（超过75%），但很少限制剂量。通过采用促进快速免疫耐受的给药方案、与对乙酰氨基酚联合用药以及晚间给药，可减轻其严重程度。通过谨慎减少剂量和偶尔的治疗休息期能最好地控制疲劳。在每次注射3×10⁶ - 18×10⁶国际单位的剂量下，干扰素α-2a治疗可在门诊安全进行，极少或无需住院。针对干扰素α-2a产生抗体的频率和滴度较低，表明它是一种弱抗原，适合长期治疗应用。
